Cipla

Cipla delivered a strong Q4 FY26 with India business growing 15% YoYCurrent reported value: 15% YoY. No comparable prior figure is available in the source record. and North America revenue of $155MCurrent reported value: $155M. No comparable prior figure is available in the source record.. The company achieved key milestones including generic Ventolin approval and crossing 12,500 CrCurrent 12,500 Cr. Reported change: +15% YoY. in India revenue. Management guided for FY27 EBITDA margins of 18.5-20%Current reported value: 18.5-20%. No comparable prior figure is available in the source record. with sequential improvement, driven by US respiratory launches and India chronic portfolio expansion. The US business targets a $1B run-rateCurrent reported value: $1B run-rate. No comparable prior figure is available in the source record. by FY27-end, supported by 4 respiratory approvals and a peptide launch. Key risk: geopolitical disruptions and war-related cost inflation could pressure near-term margins.